Preclinical and clinical development of neoantigen vaccines

Keyphrases

• Preclinical Development 100%
• Clinical Development 100%
• Neoantigen Vaccine 100%
• Neoantigen 80%
• Checkpoint Blockade Therapy 40%
• Dendritic Cells 20%
• Somatic mutation 20%
• Clinical Trials 20%
• Cancer Types 20%
• Next-generation Sequencing 20%
• Breast Cancer 20%
• CD8+ 20%
• CD4+ 20%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Cancer Immunotherapy 20%
• Synthetic Peptides 20%
• RNA-based 20%
• Immunogenicity 20%
• Human Trials 20%
• Melanoma 20%
• Immune Therapy 20%
• Immune Control 20%
• Computational Analysis 20%
• Sequencing Technology 20%
• Antigen-specific T Cell Response 20%
• Immunosuppressive Microenvironment 20%
• Peptide-based 20%
• Cancer Neoantigens 20%
• Lung-other 20%
• Long RNAs 20%
• Evolving Mechanism 20%
• Technology Analysis 20%

Immunology and Microbiology

• Neoantigen 100%
• Immunotherapy 20%
• CD8 10%
• Dendritic Cell 10%
• T Cell 10%
• CD4 10%
• Immunosuppressive Drug 10%
• Cancer Immunotherapy 10%
• Immunogenicity 10%
• Immune Escape 10%
• Somatic Mutation 10%
• Peptides 10%